I agree that this site is using cookies. You can find further informations here.
X
Bjørn, Mads Emil
262  results:
Search for persons X
?
1

Elevated levels of oxidized nucleosides in individuals with..:

Sørensen, Anders L. ; Hasselbalch, Hans C. ; Bjørn, Mads Emil...
Redox Biology.  41 (2021)  - p. 101895 , 2021
Link: https://doi.org/10.1016/..
 
?
2

Ruxolitinib and interferon-α2 combination therapy for patie..:

Sørensen, Anders Lindholm ; Mikkelsen, Stine Ulrik ; Knudsen, Trine Alma...
Haematologica.  105 (2020)  9 - p. 2262-2272 , 2020
Link: https://doi.org/10.3324/..
 
?
3

B‐cell frequencies and immunoregulatory phenotypes in myelo..:

Sørensen, Anders Lindholm ; Bjørn, Mads Emil ; Riley, Caroline H....
European Journal of Haematology.  103 (2019)  4 - p. 351-361 , 2019
Link: https://doi.org/10.1111/..
 
?
4

Safety and efficacy of combination therapy of interferon‐α2..:

Mikkelsen, Stine Ulrik ; Kjær, Lasse ; Bjørn, Mads Emil...
Cancer Medicine.  7 (2018)  8 - p. 3571-3581 , 2018
Link: https://doi.org/10.1002/..
 
?
5

Reactive oxygen species inhibit catalytic activity of pepti..:

Damgaard, Dres ; Bjørn, Mads Emil ; Jensen, Peter Østrup.
Journal of Enzyme Inhibition and Medicinal Chemistry.  32 (2017)  1 - p. 1203-1208 , 2017
Link: https://doi.org/10.1080/..
 
?
6

Reduced glutathione as a physiological co-activator in the ..:

Damgaard, Dres ; Bjørn, Mads Emil ; Steffensen, Maria A...
Arthritis Research & Therapy.  18 (2016)  1 - p. , 2016
Link: https://doi.org/10.1186/..
 
?
7

The impact of ruxolitinib treatment on inflammation‐mediate..:

Bjørn, Mads Emil ; Hasselbalch, Hans Carl
Clinical Case Reports.  3 (2015)  6 - p. 499-503 , 2015
Link: https://doi.org/10.1002/..
 
?
8

MPNs as Inflammatory Diseases: The Evidence, Consequences, ..:

Hasselbalch, Hans Carl ; Bjørn, Mads Emil
Mediators of Inflammation.  2015 (2015)  - p. 1-16 , 2015
Link: https://doi.org/10.1155/..
 
?
9

The Role of Reactive Oxygen Species in Myelofibrosis and Re..:

Bjørn, Mads Emil ; Hasselbalch, Hans Carl
Mediators of Inflammation.  2015 (2015)  - p. 1-11 , 2015
Link: https://doi.org/10.1155/..
 
?
10

Circulating YKL-40 in patients with essential thrombocythem..:

Andersen, Christen Lykkegaard ; Bjørn, Mads Emil ; McMullin, Mary Frances...
Leukemia Research.  38 (2014)  7 - p. 816-821 , 2014
Link: https://doi.org/10.1016/..
 
?
11

Circulating YKL‐40 in myelofibrosis a potential novel bioma..:

Bjørn, Mads Emil ; Andersen, Christen Lykkegaard ; Jensen, Morten Krogh.
European Journal of Haematology.  93 (2014)  3 - p. 224-228 , 2014
Link: https://doi.org/10.1111/..
 
?
12

Elevated levels of oxidized nucleosides in individuals with..:

Sørensen, Anders L ; Hasselbalch, Hans C ; Bjørn, Mads Emil...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907890/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
13

Ruxolitinib and interferon-α2 combination therapy for patie..:

Sørensen, Anders Lindholm ; Mikkelsen, Stine Ulrik ; Knudsen, Trine Alma...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556624/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
14

Ruxolitinib and interferon-α2 combination therapy for patie..:

Sørensen, Anders Lindholm ; Mikkelsen, Stine Ulrik ; Knudsen, Trine Alma...
Sørensen , A L , Mikkelsen , S U , Knudsen , T A , Bjørn , M E , Andersen , C L , Bjerrum , O W , Brochmann , N , Patel , D A , Gjerdrum , L M R , El Fassi , D , Kruse , T A , Larsen , T S , Mourits-Andersen , H T , Nielsen , C H , Ellervik , C , Pallisgaard , N , Thomassen , M , Kjær , L , Skov , V & Hasselbalch , H C 2020 , ' Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis : a phase II study ' , Haematologica , vol. 105 , no. 9 , pp. 2262-2272 . https://doi.org/10.3324/haematol.2019.235648.  , 2020
Link: https://portal.findresea..
 
?
15

Safety and efficacy of combination therapy of interferon-α2..:

Mikkelsen, Stine Ulrik ; Kjær, Lasse ; Bjørn, Mads Emil...
Mikkelsen , S U , Kjær , L , Bjørn , M E , Knudsen , T A , Sørensen , A L , Andersen , C B L , Bjerrum , O W , Brochmann , N , Fassi , D E , Kruse , T A , Larsen , T S , Mourits-Andersen , H T , Nielsen , C H , Pallisgaard , N , Thomassen , M , Skov , V & Hasselbalch , H C 2018 , ' Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis ' , Cancer Medicine , vol. 7 , no. 8 , pp. 3571-3581 . https://doi.org/10.1002/cam4.1619.  , 2018
Link: https://portal.findresea..
 
1-15